Baxter International Inc., the world's biggest maker of treatments for blood disease, settled a patent-infringement suit with Talecris Biotherapeutics Inc. over a means of preparing injectable antibodies, on the eve of trial. Talecris, based in Research Triangle Park, North Carolina, sued Baxter in federal court in Delaware in 2005 over the patent, licensed from Bayer HealthCare LLC, for a method of clearing viruses from serum to treat people with weakened immune systems. A jury trial was set to begin today in Wilmington, Delaware, before Chief U.S. District Judge Gregory M. Sleet. "I can confirm that the terms of the settlement are confidential," Talecris spokeswoman Lacy McMahon said in a statement. Baxter spokeswoman Deborah Spak said the trial was canceled and also declined to give details of the settlement. In the complaint, Talecris contended it would be "irreparably harmed" by the importation and sale of Baxter's infringing Gammagard Liquid product, and asked for a ruling to stop sales until the patent expires in 2020.

Posted by GEN-ERIC at 12:02:18 am into the following categories: In The News

---

http://gen-eric.com/patents/htsrv/trackback.php/1228

Name:

Email: (not displayed on this site)

Site/Url:

Comment text:

Allowed XHTML tags: <p, ul, ol, li, dl, dt, dd, address, blockquote, ins, del, a, span, bdo, br, em, strong, dfn, code, samp, kdb, var, cite, abbr, acronym, q, sub, sup, tt, i, b, big, small>

URLs, email, AIM and ICQs will be converted automatically.

Options:
Auto-BR (Line breaks become <br />)
Remember me (Set cookies for name, email & url)